Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome [PDF]
, 2013 Background Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types.
Banypersad, SM +15 more
core +1 more source
A case of fatal familial edema
IHJ Cardiovascular Case Reports, 2023 Cardiac amyloidosis is an often-underdiagnosed cause of heart failure, and associated morbidity and mortality. AL (Primary amyloidosis) and ATTR (Amyloidosis, hereditary, transthyretin-related) variants most commonly affect the heart amongst the ...
Sriram Easwaran +4 more
doaj +1 more source
Utility of Genetic Testing in Patients with Transthyretin Amyloid Cardiomyopathy: A Brief Review
Biomedicines, 2023 Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly diagnosed condition. Although wild-type transthyretin amyloidosis (ATTRwt) is the most common ATTR-CM, hereditary transthyretin amyloidosis (ATTRv) may also occur.
Ana-Maria Merino-Merino +4 more
doaj +1 more source
Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis [PDF]
, 2016 Search strategy.
Lei Zhao, Quan Fang, Zhuang Tian
core +2 more sources
Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide [PDF]
, 2018 The aim of this study is to assess the prevalence of cardiac involvement in hereditary transthyretin-derived (ATTRm) amyloidosis at the time of diagnosis and to determine the diagnostic and clinical value of N-terminal pro-B-type natriuretic peptide (NT ...
Blokzijl, Hans +7 more
core +2 more sources
Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds [PDF]
, 2018 PURPOSE: 18F-Florbetapir has been reported to show cardiac uptake in patients with systemic light-chain amyloidosis (AL). This study systematically assessed uptake of 18F-florbetapir in patients with proven systemic amyloidosis at sites outside the heart.
Burniston, M +8 more
core +1 more source
Cardiology and Therapy, 2023 Introduction Transthyretin amyloidosis (ATTR amyloidosis) is primarily associated with a cardiac or neurologic phenotype, but a mixed phenotype is increasingly described.
Juan González-Moreno +13 more
doaj +1 more source
Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. [PDF]
, 2015 Cardiac involvement determines outcome in patients with systemic amyloidosis. There is major unmet need for quantification of cardiac amyloid burden, which is currently only met in part through semi-quantitative bone scintigraphy or Cardiovascular ...
Bandula, S +10 more
core +1 more source
ESC Heart Failure, 2023 While patients with transthyretin cardiac amyloidosis (ATTR‐CA) typically present with concentric or asymmetric hypertrophy, a small percentage of ATTR‐CA is known to present with ‘atypical’ cardiac morphologies such as eccentric hypertrophy or even no ...
Takuma Iwaya +6 more
doaj +1 more source
Urinary Biomarkers for Kidney Disease in ATTR Amyloidosis [PDF]
, 2014 Aim: The detection and prognosis of nephropathy in transthyretin amyloidosis depends on albuminuria and renal function. Knowing that urinary levels of alpha-1 microglobulin and beta-2 microglobulin reflect tubular dysfunction while urinary alpha-2 ...
Beirão, I. +5 more
core +1 more source